Serum type XVI collagen is associated with colorectal cancer and ulcerative colitis indicating a pathological role in gastrointestinal disorders

Christina Jensen*, Signe H. Nielsen, Joachim H. Mortensen, Jens Kjeldsen, Lone G. Klinge, Aleksander Krag, Henrik Harling, Lars N. Jørgensen, Morten A. Karsdal, Nicholas Willumsen

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

87 Downloads (Pure)

Resumé

Altered extracellular matrix (ECM) remodeling is an important part of the pathology of gastrointestinal (GI) disorders. In the intestine, type XVI collagen (col-16) plays a role in pathogenesis by affecting ECM architecture and induce cell invasion. Measuring col-16 in serum may therefore have biomarker potential in GI disorders such as colorectal cancer (CRC) and ulcerative colitis (UC). The aim of this study was to determine whether col-16 can serve as a biomarker for altered ECM remodeling in patients with CRC and UC. A monoclonal antibody was raised against the C-terminal end of col-16 (PRO-C16), and a competitive enzyme-linked immunosorbent assay (ELISA) was developed and technically validated. Levels of PRO-C16 were measured in serum from patients with CRC (before (n = 50) and 3 months after (n = 23) tumor resections), UC (n = 39) and healthy controls (n = 50). The PRO-C16 ELISA was specific toward the C-terminal of col-16. PRO-C16 was significantly elevated both in serum from patients with CRC (P = 0.0026) and UC (P < 0.0001) compared to controls. No difference was detected in levels of PRO-C16 between patients with CRC at baseline and 3 months after tumor resections (P > 0.999). Levels of PRO-C16 identified patients with a GI disorder with a positive predictive value of 0.9 and an odds ratio of 12 (95%CI = 4.5-29.5, P < 0.0001). The newly developed assay detected significantly elevated levels of PRO-C16 in serum from patients with GI disorders compared to controls suggesting its potential as a biomarker in this setting. Future studies are needed to validate these findings.

OriginalsprogEngelsk
TidsskriftCancer Medicine
Vol/bind7
Udgave nummer9
Sider (fra-til)4619-4626
ISSN2045-7634
DOI
StatusUdgivet - 20. aug. 2018

Fingeraftryk

Ulcerative Colitis
Colorectal Neoplasms
Serum
Intestines
Odds Ratio
Pathology
Neoplasms

Citer dette

Jensen, Christina ; Nielsen, Signe H. ; Mortensen, Joachim H. ; Kjeldsen, Jens ; Klinge, Lone G. ; Krag, Aleksander ; Harling, Henrik ; Jørgensen, Lars N. ; Karsdal, Morten A. ; Willumsen, Nicholas. / Serum type XVI collagen is associated with colorectal cancer and ulcerative colitis indicating a pathological role in gastrointestinal disorders. I: Cancer Medicine. 2018 ; Bind 7, Nr. 9. s. 4619-4626.
@article{4f9b838cf17d4a25bc2b80602d80e95f,
title = "Serum type XVI collagen is associated with colorectal cancer and ulcerative colitis indicating a pathological role in gastrointestinal disorders",
abstract = "Altered extracellular matrix (ECM) remodeling is an important part of the pathology of gastrointestinal (GI) disorders. In the intestine, type XVI collagen (col-16) plays a role in pathogenesis by affecting ECM architecture and induce cell invasion. Measuring col-16 in serum may therefore have biomarker potential in GI disorders such as colorectal cancer (CRC) and ulcerative colitis (UC). The aim of this study was to determine whether col-16 can serve as a biomarker for altered ECM remodeling in patients with CRC and UC. A monoclonal antibody was raised against the C-terminal end of col-16 (PRO-C16), and a competitive enzyme-linked immunosorbent assay (ELISA) was developed and technically validated. Levels of PRO-C16 were measured in serum from patients with CRC (before (n = 50) and 3 months after (n = 23) tumor resections), UC (n = 39) and healthy controls (n = 50). The PRO-C16 ELISA was specific toward the C-terminal of col-16. PRO-C16 was significantly elevated both in serum from patients with CRC (P = 0.0026) and UC (P < 0.0001) compared to controls. No difference was detected in levels of PRO-C16 between patients with CRC at baseline and 3 months after tumor resections (P > 0.999). Levels of PRO-C16 identified patients with a GI disorder with a positive predictive value of 0.9 and an odds ratio of 12 (95{\%}CI = 4.5-29.5, P < 0.0001). The newly developed assay detected significantly elevated levels of PRO-C16 in serum from patients with GI disorders compared to controls suggesting its potential as a biomarker in this setting. Future studies are needed to validate these findings.",
keywords = "Biomarkers, Collagen, Colorectal cancer, Extracellular matrix, Ulcerative colitis",
author = "Christina Jensen and Nielsen, {Signe H.} and Mortensen, {Joachim H.} and Jens Kjeldsen and Klinge, {Lone G.} and Aleksander Krag and Henrik Harling and J{\o}rgensen, {Lars N.} and Karsdal, {Morten A.} and Nicholas Willumsen",
year = "2018",
month = "8",
day = "20",
doi = "10.1002/cam4.1692",
language = "English",
volume = "7",
pages = "4619--4626",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "JohnWiley & Sons Ltd.",
number = "9",

}

Serum type XVI collagen is associated with colorectal cancer and ulcerative colitis indicating a pathological role in gastrointestinal disorders. / Jensen, Christina; Nielsen, Signe H.; Mortensen, Joachim H.; Kjeldsen, Jens; Klinge, Lone G.; Krag, Aleksander; Harling, Henrik; Jørgensen, Lars N.; Karsdal, Morten A.; Willumsen, Nicholas.

I: Cancer Medicine, Bind 7, Nr. 9, 20.08.2018, s. 4619-4626.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Serum type XVI collagen is associated with colorectal cancer and ulcerative colitis indicating a pathological role in gastrointestinal disorders

AU - Jensen, Christina

AU - Nielsen, Signe H.

AU - Mortensen, Joachim H.

AU - Kjeldsen, Jens

AU - Klinge, Lone G.

AU - Krag, Aleksander

AU - Harling, Henrik

AU - Jørgensen, Lars N.

AU - Karsdal, Morten A.

AU - Willumsen, Nicholas

PY - 2018/8/20

Y1 - 2018/8/20

N2 - Altered extracellular matrix (ECM) remodeling is an important part of the pathology of gastrointestinal (GI) disorders. In the intestine, type XVI collagen (col-16) plays a role in pathogenesis by affecting ECM architecture and induce cell invasion. Measuring col-16 in serum may therefore have biomarker potential in GI disorders such as colorectal cancer (CRC) and ulcerative colitis (UC). The aim of this study was to determine whether col-16 can serve as a biomarker for altered ECM remodeling in patients with CRC and UC. A monoclonal antibody was raised against the C-terminal end of col-16 (PRO-C16), and a competitive enzyme-linked immunosorbent assay (ELISA) was developed and technically validated. Levels of PRO-C16 were measured in serum from patients with CRC (before (n = 50) and 3 months after (n = 23) tumor resections), UC (n = 39) and healthy controls (n = 50). The PRO-C16 ELISA was specific toward the C-terminal of col-16. PRO-C16 was significantly elevated both in serum from patients with CRC (P = 0.0026) and UC (P < 0.0001) compared to controls. No difference was detected in levels of PRO-C16 between patients with CRC at baseline and 3 months after tumor resections (P > 0.999). Levels of PRO-C16 identified patients with a GI disorder with a positive predictive value of 0.9 and an odds ratio of 12 (95%CI = 4.5-29.5, P < 0.0001). The newly developed assay detected significantly elevated levels of PRO-C16 in serum from patients with GI disorders compared to controls suggesting its potential as a biomarker in this setting. Future studies are needed to validate these findings.

AB - Altered extracellular matrix (ECM) remodeling is an important part of the pathology of gastrointestinal (GI) disorders. In the intestine, type XVI collagen (col-16) plays a role in pathogenesis by affecting ECM architecture and induce cell invasion. Measuring col-16 in serum may therefore have biomarker potential in GI disorders such as colorectal cancer (CRC) and ulcerative colitis (UC). The aim of this study was to determine whether col-16 can serve as a biomarker for altered ECM remodeling in patients with CRC and UC. A monoclonal antibody was raised against the C-terminal end of col-16 (PRO-C16), and a competitive enzyme-linked immunosorbent assay (ELISA) was developed and technically validated. Levels of PRO-C16 were measured in serum from patients with CRC (before (n = 50) and 3 months after (n = 23) tumor resections), UC (n = 39) and healthy controls (n = 50). The PRO-C16 ELISA was specific toward the C-terminal of col-16. PRO-C16 was significantly elevated both in serum from patients with CRC (P = 0.0026) and UC (P < 0.0001) compared to controls. No difference was detected in levels of PRO-C16 between patients with CRC at baseline and 3 months after tumor resections (P > 0.999). Levels of PRO-C16 identified patients with a GI disorder with a positive predictive value of 0.9 and an odds ratio of 12 (95%CI = 4.5-29.5, P < 0.0001). The newly developed assay detected significantly elevated levels of PRO-C16 in serum from patients with GI disorders compared to controls suggesting its potential as a biomarker in this setting. Future studies are needed to validate these findings.

KW - Biomarkers

KW - Collagen

KW - Colorectal cancer

KW - Extracellular matrix

KW - Ulcerative colitis

U2 - 10.1002/cam4.1692

DO - 10.1002/cam4.1692

M3 - Journal article

C2 - 30030909

AN - SCOPUS:85050493015

VL - 7

SP - 4619

EP - 4626

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 9

ER -